SOFINNOVA-PARTNERS
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the launch of Biovelocita, an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.
Biovelocita’s newly formed team will provide a hands-on, robust framework for startups, combining direct management, financial backing, and access to Sofinnova’s extensive infrastructure and network. The strategy builds upon Sofinnova’s established track record of nurturing innovative ventures within the healthcare and sustainability sectors. It draws inspiration from the achievements of Italy’s first biotech accelerator, BiovelocITA, co-founded by Gabriella Camboni, Silvano Spinelli and Sofinnova Partners in 2015, which has significantly contributed to the growth of the Italian biotech ecosystem.
Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: “With Sofinnova Biovelocita, we are doubling down on our commitment to innovation and company creation in the life sciences. To improve and expand our company-creation toolbox, we have brought together a group of experienced investors and entrepreneurs who have been collaborating with Sofinnova for over a decade, some nearly two decades. With this top-tier team, we look forward to strengthening one of Sofinnova’s strategic pillars: acceleration, which is already making rapid strides in the medical device space with Sofinnova MD Start, our in-house medtech accelerator.”
Key partners of this initiative include:
- Gabriella Camboni, Partner, pivotal in the conception of this strategy as a co-founder and CEO of BiovelocITA. She also co-founded two Sofinnova companies, EOS (Ethical Oncology Science), serving as its COO until its acquisition by Clovis Oncology in 2013, and Novuspharma, which was acquired by Cell Therapeutics, Inc. in 2003.
- Matthieu Coutet, Partner, brings nearly two decades of experience in venture capital and operations, including significant contributions to the launch of biotech startups such as TherAchon and Annapurna Therapeutics, and the founding of AdBio Partners.
- Alex Leech, Partner, an experienced biopharma company builder and a serial CEO, most recently serving as the founding CEO of Alchemab Therapeutics, which raised an $82m Series A investment round.
- Zhizhong (Joel) Yao, Partner, a former Principal in the Sofinnova Capital Strategy, and a Kauffman Fellow, instrumental in the launch of several biotech start-ups. Holds a Harvard PhD in Chemical Biology and Systems Biology and did post-doctoral research at the French National Institute of Agricultural Research.
Seghezzi concluded: “We know from our extensive experience that close cooperation between top management teams, world-class scientists, and dedicated financing, forges the path for biotech champions of tomorrow. With this new strategy, we are poised to catalyze transformative innovation in biotechnology.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231212907842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JPMorganChase to Expand Paris Office Space15.5.2025 10:30:00 CEST | Press release
Firm signs a long term lease on a new building at 37 Place du Marché Saint-Honoré, while retaining its French headquarters at 14 Place VendômeTotalling 16,000 square-metres, this new building will have large open floors and modern amenities across five storeys and a capacity of 1,000 employeesNew office reflects a continued long term commitment to the city, and reflects wider investments in France where the firm has invested over $100 million through business and philanthropic partnerships since 2018 JPMorganChase today announces that it has signed a lease on a new building in Paris at 37 Place du Marché Saint-Honoré as the firm has passed over 1,000 employees in the city. The new office is situated behind the bank’s headquarters at 14 Place Vendôme, and is opposite 21 Place du Marché Saint-Honoré, where the bank also has employees. While this investment will see the firm reduce the buildings it occupies in central Paris from six to just three, overall office space will increase signif
Arion Bank Strengthens Compliance With Volante Technologies’ Payments as a Service15.5.2025 10:16:00 CEST | Press release
Iceland’s leading bank strengthens its modern payments infrastructure and partners with Volante to support long-term innovation and growth Volante Technologies, the global leader in Payments as a Service (PaaS), announced a strategic partnership with Iceland’s leading financial institution, Arion Bank, to modernise and future-proof the bank's payments infrastructure, solidify its regulatory response, and prepare for an increase in transaction volume as part of its growth plan. Arion Bank is one of Iceland's leading financial institutions and the third-largest bank in the country by assets. It offers a wide range of services in retail, corporate, and investment banking, providing smart and reliable financial solutions to individuals and businesses alike. The bank sought to evolve its current payments hub by adopting a modern, API-driven, and scalable solution designed to support multi-rail processing and seamless integration with the emerging payments ecosystem. By partnering with Volan
ITEN and A*STAR IME Announce Breakthrough in Solid-State Battery Integration for Advanced Packaging15.5.2025 09:00:00 CEST | Press release
ITEN, a global leader in micro solid-state batteries, and A*STAR Institute of Microelectronics (A*STAR IME), a leader in advanced packaging research, have announced a groundbreaking achievement for the integration of ITEN’s micro batteries using A*STAR IME’s cutting-edge advanced packaging platform. This milestone paves the way for in-package energy storage solutions, enabling more efficient, compact, and reliable system-in-package (SiP) designs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515958544/en/ Revolutionizing Energy Storage and Advanced Packaging This breakthrough innovation represents a significant leap forward in SiP technology. By embedding ITEN’s high-performance solid-state batteries at the wafer level, ITEN and A*STAR IME have successfully demonstrated integrating non-volatile energy storage directly using advanced packaging. This enables seamless integration, elevating energy efficiency and operational
Equiduct Expands into the Swiss Market15.5.2025 08:00:00 CEST | Press release
Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd. Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct’s pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear. This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as dire
Allianz Reports Record Operating Profit and Is Fully on Track to Achieve Full-Year Outlook15.5.2025 07:26:00 CEST | Press release
May 15, 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514121549/en/ Oliver Bäte, Chief Executive Officer of Allianz SE (Photo: Allianz SE) 1Q 2025 Total business volume advances 11.71 percent to 54.0 billion euros reflecting sustained momentum across all segments Operating profit increases 6.3 percent to 4.2 billion euros, reaching 26 percent of our full-year outlook midpoint Shareholders’ core net income is stable at a very good level of 2.6 billion euros. Adjusted for a one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures, shareholders’ core net income is up 5 percent Core earnings per share grow 2.9 percent and reach 6.61 euros. Adjusted for the above-mentioned one-off tax provision, core earnings per share are up 7 percent Annualized core RoE is robust at 16.6 percent, or 17.2 percent adjusted for the effect of the one-off tax provision Solvency II capitalization ratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom